Kazuhiro Tsuruma

Kazuhiro Tsuruma

Auto-generated profile, based on publicly available information

Kazuhiro Tsuruma

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2013 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
HTHirotaka Tanaka
Hirotaka Tanaka
MSMasamitsu Shimazawa
Masamitsu Shimazawa
MTMasafumi Takata
Masafumi Takata
HKHideo Kaneko
Hideo Kaneko
KTKazuhiro Tsuruma
Kazuhiro Tsuruma
HHHideaki Hara
Hideaki Hara

31 March 2016 in Scientific Reports
Verified
Journal Article
Open access
YKYoshiki Kuse
Yoshiki Kuse
KTKazuhiro Tsuruma
Kazuhiro Tsuruma
SSSou Sugitani
Sou Sugitani
HIHiroshi Izawa
Hiroshi Izawa
YOYuta Ohno
Yuta Ohno
HHHideaki Hara
Hideaki Hara
Progranulin (PGRN) is a secreted growth factor associated with embryo development, tissue repair and inflammation. In a previous study, we showed that adipose-derived stem cell-conditioned medium (ASC-CM) is rich in PGRN. In the present study, we investigated whether PGRN is associated with retinal regeneration in the mammalian retina. We evaluated the effect of ASC-CM using the N-methyl-N-nitrosourea-induced retinal damage model in mice. ASC-CM promoted the differentiation of photoreceptor cells following retinal damage. PGRN increased the number of BrdU+ cells in the outer nuclear layer following retinal damage some of which were Rx (retinal precursor cell marker) positive. PGRN also increased the number of rhodopsin+ photoreceptor cells in primary retinal cell cultures. SU11274, a hepatocyte growth factor (HGF) receptor inhibitor, attenuated the increase. These findings suggest that PGRN may affect the differentiation of retinal precursor cells to photoreceptor cells through the HGF receptor signaling pathway.

29 July 2011 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
RURumi Uchibayashi
Rumi Uchibayashi
KTKazuhiro Tsuruma
Kazuhiro Tsuruma
YIYuta Inokuchi
Yuta Inokuchi
MSMasamitsu Shimazawa
Masamitsu Shimazawa
HHHideaki Hara
Hideaki Hara

11 November 2010 in BioFactors
Verified
Journal Article
Closed access
PDF file
YNYasushi Nishioka
Yasushi Nishioka
AOAtsushi Oyagi
Atsushi Oyagi
KTKazuhiro Tsuruma
Kazuhiro Tsuruma
MSMasamitsu Shimazawa
Masamitsu Shimazawa
TITakashi Ishibashi
Takashi Ishibashi
HHHideaki Hara
Hideaki Hara

11 October 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
Yuhei NishimuraYuhei Nishimura
Yuhei Nishimura
MTMasaaki Tagawa
Masaaki Tagawa
HIHideki Ito
Hideki Ito
KTKazuhiro Tsuruma
Kazuhiro Tsuruma
HHHideaki Hara
Hideaki Hara
Drug repositioning (DR) is the process of identifying new indications for existing drugs. DR usually focuses on drugs that have cleared phase-I safety trials but has yet to show efficacy for the intended indication. Therefore, DR can probably skip the preclinical and phase-I study, which can reduce the cost throughout drug development. However, the expensive phase-II/III trials are required to establish efficacy. The obstacles to DR include identification of new indications with a high success rate in clinical studies, obtaining funding for clinical studies, patent protection, and approval systems. To tackle these obstacles, various approaches have been applied to DR worldwide. In this perspective, we provide representative examples of DR and discuss the ongoing efforts to overcome obstacles to DR in Japan.

1 February 2018 in Experimental Eye Research
Verified
Journal Article
Closed access
TITomoyo Imamura
Tomoyo Imamura
KTKazuhiro Tsuruma
Kazuhiro Tsuruma
YIYuki Inoue
Yuki Inoue
TOTomohiro Otsuka
Tomohiro Otsuka
YOYuta Ohno
Yuta Ohno
HHHideaki Hara
Hideaki Hara